{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:11:11Z","timestamp":1788891071892,"version":"build-2803163510"},"reference-count":122,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03508-1","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T16:53:47Z","timestamp":1788886427000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advances and Hurdles of PLGA-Based Therapy for Pancreatic Cancer"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3704-0941","authenticated-orcid":false,"given":"Nusaiba","family":"Al-Nemrawi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7852-2604","authenticated-orcid":false,"given":"Ghena Majdi","family":"AbuAlna\u2019aj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5439-7928","authenticated-orcid":false,"given":"Razan Ahmad","family":"AL Hazaimeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9649-5735","authenticated-orcid":false,"given":"Shaikha Adnan","family":"Al-Quraan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1535-7103","authenticated-orcid":false,"given":"Noor Ahmad Bani","family":"Yaseen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2279-6655","authenticated-orcid":false,"given":"Fatima","family":"Hameedat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0484-2315","authenticated-orcid":false,"given":"Fl\u00e1via","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"issue":"4","key":"3508_CR1","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3390\/jcm14041129","volume":"14","author":"U Hayat","year":"2025","unstructured":"Hayat U, Croce PS, Saadeh A, Desai K, Appiah J, Khan S, et al. Current and emerging treatment options for pancreatic cancer: a comprehensive review. J Clin Med. 2025;14(4):1129.","journal-title":"J Clin Med"},{"issue":"1","key":"3508_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Primers. 2016;2(1):1\u201322.","journal-title":"Nat Rev Dis Primers"},{"issue":"27","key":"3508_CR3","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.3748\/wjg.v27.i27.4298","volume":"27","author":"J-X Hu","year":"2021","unstructured":"Hu J-X, Zhao C-F, Chen W-B, Liu Q-C, Li Q-W, Lin Y-Y, et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol. 2021;27(27):4298.","journal-title":"World J Gastroenterol"},{"key":"3508_CR4","doi-asserted-by":"crossref","unstructured":"Narayanan G, Ruiz E, Scagnelli T, van der Lei S. Pancreatic cancer. In: Digestive disease interventions. Springer; 2026. p. 321\u201338.","DOI":"10.1007\/978-3-032-03935-4_22"},{"issue":"19","key":"3508_CR5","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.3748\/wjg.v24.i19.2047","volume":"24","author":"L Zhang","year":"2018","unstructured":"Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. World J Gastroenterol. 2018;24(19):2047.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3508_CR6","doi-asserted-by":"publisher","first-page":"552","DOI":"10.5958\/0974-360X.2021.00100.1","volume":"14","author":"B Jagadeesan","year":"2021","unstructured":"Jagadeesan B, Haran PH, Praveen D, Chowdary PR, Aanandhi MV. A comprehensive review on pancreatic cancer. Res J Pharm Technol. 2021;14(1):552\u20134.","journal-title":"Res J Pharm Technol"},{"issue":"6","key":"3508_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/PPO.0000000000000290","volume":"23","author":"LC Chu","year":"2017","unstructured":"Chu LC, Goggins MG, Fishman EK. Diagnosis and detection of pancreatic cancer. Cancer J. 2017;23(6):333\u201342.","journal-title":"Cancer J"},{"key":"3508_CR8","doi-asserted-by":"publisher","first-page":"153303382096211","DOI":"10.1177\/1533033820962117","volume":"19","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Liu W. Pancreatic cancer: a review of risk factors, diagnosis, and treatment. Technol Cancer Res Treat. 2020;19:1533033820962117.","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"3508_CR9","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3109\/0284186X.2015.1068445","volume":"55","author":"KJ Labori","year":"2016","unstructured":"Labori KJ, Katz MH, Tzeng CW, Bj\u00f8rnbeth BA, Cvancarova M, Edwin B, et al. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma \u2013 A population-based cohort study. Acta Oncol. 2016;55(3):265\u201377.","journal-title":"Acta Oncol"},{"issue":"18","key":"3508_CR10","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.3390\/ijms20184504","volume":"20","author":"S Zeng","year":"2019","unstructured":"Zeng S, P\u00f6ttler M, Lan B, Gr\u00fctzmann R, Pilarsky C, Yang H. Chemoresistance in pancreatic cancer. Int J Mol Sci. 2019;20(18):4504.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"3508_CR11","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/pharmaceutics11110574","volume":"11","author":"K Samanta","year":"2019","unstructured":"Samanta K, Setua S, Kumari S, Jaggi M, Yallapu MM, Chauhan SC. Gemcitabine combination nano therapies for pancreatic cancer. Pharmaceutics. 2019;11(11):574.","journal-title":"Pharmaceutics"},{"issue":"43","key":"3508_CR12","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.3748\/wjg.v24.i43.4846","volume":"24","author":"A McGuigan","year":"2018","unstructured":"McGuigan A, Kelly P, Turkington RC, Jones C, Coleman HG, McCain RS. Pancreatic cancer: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2018;24(43):4846.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"3508_CR13","doi-asserted-by":"publisher","first-page":"2219864","DOI":"10.1080\/10717544.2023.2219864","volume":"30","author":"R Martinez-Borrajo","year":"2023","unstructured":"Martinez-Borrajo R, Diaz-Rodriguez P, Landin M. Rationalized design to explore the full potential of PLGA microspheres as drug delivery systems. Drug Delivery. 2023;30(1):2219864.","journal-title":"Drug Delivery"},{"issue":"9\u201310","key":"3508_CR14","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1166\/jnn.2006.479","volume":"6","author":"D Moinard-Checot","year":"2006","unstructured":"Moinard-Checot D, Chevalier Y, Brian\u00e7on S, Fessi H, Guinebreti\u00e8re S. Nanoparticles for drug delivery: review of the formulation and process difficulties illustrated by the emulsion-diffusion process. J Nanosci Nanotechnol. 2006;6(9\u201310):2664\u201381.","journal-title":"J Nanosci Nanotechnol"},{"issue":"8","key":"3508_CR15","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1039\/D3NR00280B","volume":"15","author":"T Chen","year":"2023","unstructured":"Chen T, Peng Y, Qiu M, Yi C, Xu Z. Recent advances in mixing-induced nanoprecipitation: from creating complex nanostructures to emerging applications beyond biomedicine. Nanoscale. 2023;15(8):3594\u2013609.","journal-title":"Nanoscale"},{"issue":"8","key":"3508_CR16","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1023\/B:PHAM.0000036917.75634.be","volume":"21","author":"S Galindo-Rodriguez","year":"2004","unstructured":"Galindo-Rodriguez S, All\u00e9mann E, Fessi H, Doelker E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharm Res. 2004;21(8):1428\u201339.","journal-title":"Pharm Res"},{"issue":"1","key":"3508_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/00914037.2021.1985495","volume":"72","author":"SR Pardeshi","year":"2023","unstructured":"Pardeshi SR, Nikam A, Chandak P, Mandale V, Naik JB, Giram PS. Recent advances in PLGA based nanocarriers for drug delivery system: a state of the art review. Int J Polym Mater. 2023;72(1):49\u201378.","journal-title":"Int J Polym Mater"},{"key":"3508_CR18","doi-asserted-by":"crossref","unstructured":"Ainurofiq A, Wiyono N, Vania Febrianti Marzuki A, Choiri S, editors. Screening and assessment of the chitosan-based nanoparticle formation through an ionic gelation method. Journal of Physics: Conference Series; 2025: IOP Publishing.","DOI":"10.1088\/1742-6596\/2945\/1\/012046"},{"key":"3508_CR19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.partic.2023.03.003","volume":"84","author":"GT Vladisavljevi\u0107","year":"2024","unstructured":"Vladisavljevi\u0107 GT. Preparation of microparticles and nanoparticles using membrane-assisted dispersion, micromixing, and evaporation processes. Particuology. 2024;84:30\u201344.","journal-title":"Particuology"},{"issue":"3","key":"3508_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.3390\/polym3031377","volume":"3","author":"HK Makadia","year":"2011","unstructured":"Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377\u201397.","journal-title":"Polymers (Basel)"},{"issue":"1","key":"3508_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41120-022-00060-7","volume":"8","author":"M Alvi","year":"2022","unstructured":"Alvi M, Yaqoob A, Rehman K, Shoaib SM, Akash MSH. PLGA-based nanoparticles for the treatment of cancer: current strategies and perspectives. AAPS Open. 2022;8(1):12.","journal-title":"AAPS Open"},{"key":"3508_CR22","doi-asserted-by":"publisher","first-page":"990505","DOI":"10.3389\/fphar.2022.990505","volume":"13","author":"D Zhang","year":"2022","unstructured":"Zhang D, Liu L, Wang J, Zhang H, Zhang Z, Xing G, et al. Drug-loaded PEG-PLGA nanoparticles for cancer treatment. Front Pharmacol. 2022;13:990505.","journal-title":"Front Pharmacol"},{"issue":"2","key":"3508_CR23","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1021\/nl404391r","volume":"14","author":"S Kunjachan","year":"2014","unstructured":"Kunjachan S, Pola R, Gremse F, Theek B, Ehling J, Moeckel D, et al. Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett. 2014;14(2):972\u201381.","journal-title":"Nano Lett"},{"key":"3508_CR24","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.trac.2015.06.014","volume":"80","author":"S Sharma","year":"2016","unstructured":"Sharma S, Parmar A, Kori S, Sandhir R. PLGA-based nanoparticles: A new paradigm in biomedical applications. TrAC Trends Anal Chem. 2016;80:30\u201340.","journal-title":"TrAC Trends Anal Chem"},{"issue":"2","key":"3508_CR25","doi-asserted-by":"publisher","first-page":"517","DOI":"10.7314\/APJCP.2014.15.2.517","volume":"15","author":"F Sadat Tabatabaei Mirakabad","year":"2014","unstructured":"Sadat Tabatabaei Mirakabad F, Nejati-Koshki K, Akbarzadeh A, Yamchi MR, Milani M, Zarghami N, et al. PLGA-based nanoparticles as cancer drug delivery systems. Asian Pac J Cancer Prev. 2014;15(2):517\u201335.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"32","key":"3508_CR26","doi-asserted-by":"publisher","first-page":"1701255","DOI":"10.1002\/adfm.201701255","volume":"27","author":"L Song","year":"2017","unstructured":"Song L, Zhao N, Xu F-J. Hydroxyl-rich polycation brushed multifunctional rare-earth-gold core-shell nanorods for versatile therapy platforms. Adv Func Mater. 2017;27(32):1701255.","journal-title":"Adv Func Mater"},{"issue":"2","key":"3508_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jconrel.2012.01.043","volume":"161","author":"F Danhier","year":"2012","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release. 2012;161(2):505\u201322.","journal-title":"J Control Release"},{"issue":"11","key":"3508_CR28","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.clinthera.2017.08.015","volume":"39","author":"MT Saung","year":"2017","unstructured":"Saung MT, Zheng L. Current standards of chemotherapy for pancreatic cancer. Clin Ther. 2017;39(11):2125\u201334.","journal-title":"Clin Ther"},{"issue":"2","key":"3508_CR29","doi-asserted-by":"publisher","first-page":"C540","DOI":"10.1152\/ajpcell.00331.2022","volume":"324","author":"AK Beutel","year":"2023","unstructured":"Beutel AK, Halbrook CJ. Barriers and opportunities for gemcitabine in pancreatic cancer therapy. Am J Physiol Cell Physiol. 2023;324(2):C540\u201352.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"1","key":"3508_CR30","doi-asserted-by":"publisher","first-page":"3687700","DOI":"10.1155\/2021\/3687700","volume":"2021","author":"J Sharifi-Rad","year":"2021","unstructured":"Sharifi-Rad J, Quispe C, Patra JK, Singh YD, Panda MK, Das G, et al. Paclitaxel: Application in modern oncology and nanomedicine-based cancer therapy. Oxid Med Cell Longev. 2021;2021(1):3687700.","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"3508_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12885-018-4393-7","volume":"18","author":"S-t Wu","year":"2018","unstructured":"Wu S-t, Fowler AJ, Garmon CB, Fessler AB, Ogle JD, Grover KR, et al. Treatment of pancreatic ductal adenocarcinoma with tumor antigen specific-targeted delivery of paclitaxel loaded PLGA nanoparticles. BMC Cancer. 2018;18(1):457.","journal-title":"BMC Cancer"},{"issue":"1","key":"3508_CR32","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/10717544.2019.1628118","volume":"26","author":"A Banstola","year":"2019","unstructured":"Banstola A, Pham TT, Jeong J-H, Yook S. Polydopamine-tailored paclitaxel-loaded polymeric microspheres with adhered NIR-controllable gold nanoparticles for chemo-phototherapy of pancreatic cancer. Drug Delivery. 2019;26(1):629\u201340.","journal-title":"Drug Delivery"},{"issue":"3","key":"3508_CR33","doi-asserted-by":"publisher","first-page":"166","DOI":"10.37047\/jos.2022-94097","volume":"9","author":"BG de Liyis","year":"2023","unstructured":"de Liyis BG, Mareska V, Ahmad CA, Windiarto AC, Indrayani AW. Nab-paclitaxel-loaded poly (Lactic-Co-Glycolic Acid) nanoparticles as microtubule B-tubulin stabilizer in the management of pancreatic cancer. J Oncol Sci. 2023;9(3):166\u201375.","journal-title":"J Oncol Sci"},{"issue":"7","key":"3508_CR34","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1021\/acs.molpharmaceut.0c01225","volume":"18","author":"H Cai","year":"2021","unstructured":"Cai H, Wang R, Guo X, Song M, Yan F, Ji B, et al. Combining gemcitabine-loaded macrophage-like nanoparticles and erlotinib for pancreatic cancer therapy. Mol Pharm. 2021;18(7):2495\u2013506.","journal-title":"Mol Pharm"},{"issue":"5","key":"3508_CR35","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1080\/03639045.2019.1569040","volume":"45","author":"A Jamil","year":"2019","unstructured":"Jamil A, AamirMirza M, Anwer MK, Thakur PS, Alshahrani SM, Alshetaili AS, et al. Co-delivery of gemcitabine and simvastatin through PLGA polymeric nanoparticles for the treatment of pancreatic cancer: in-vitro characterization, cellular uptake, and pharmacokinetic studies. Drug Dev Ind Pharm. 2019;45(5):745\u201353.","journal-title":"Drug Dev Ind Pharm"},{"key":"3508_CR36","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.msec.2019.01.026","volume":"98","author":"A Saneja","year":"2019","unstructured":"Saneja A, Kumar R, Mintoo MJ, Dubey RD, Sangwan PL, Mondhe DM, et al. Gemcitabine and betulinic acid co-encapsulated PLGA\u2212 PEG polymer nanoparticles for improved efficacy of cancer chemotherapy. Mater Sci Eng C Mater Biol Appl. 2019;98:764\u201371.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"18","key":"3508_CR37","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"key":"3508_CR38","doi-asserted-by":"publisher","first-page":"625084","DOI":"10.3389\/fphar.2021.625084","volume":"12","author":"S Bao","year":"2021","unstructured":"Bao S, Zheng H, Ye J, Huang H, Zhou B, Yao Q, et al. Dual targeting EGFR and STAT3 with erlotinib and alantolactone co-loaded PLGA nanoparticles for pancreatic cancer treatment. Front Pharmacol. 2021;12:625084.","journal-title":"Front Pharmacol"},{"issue":"19","key":"3508_CR39","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325.","journal-title":"N Engl J Med"},{"key":"3508_CR40","doi-asserted-by":"crossref","unstructured":"Sudha T, Bharali DJ, Yalcin M, Darwish NH, Debreli Coskun M, Keating KA, et al. Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac. Int J Nanomed. 2017:1305\u201315.","DOI":"10.2147\/IJN.S123742"},{"issue":"1","key":"3508_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1021\/acsanm.9b01921","volume":"3","author":"K Saini","year":"2020","unstructured":"Saini K, Bandyopadhyaya R. Transferrin-Conjugated Polymer-Coated Mesoporous Silica Nanoparticles Loaded with Gemcitabine for Killing Pancreatic Cancer Cells. ACS Appl Nano Mater. 2020;3(1):229\u201340.","journal-title":"ACS Appl Nano Mater"},{"issue":"17","key":"3508_CR42","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.3390\/ma14174917","volume":"14","author":"A Markowski","year":"2021","unstructured":"Markowski A, Migda\u0142 P, Zygmunt A, Zaremba-Czogalla M, Gubernator J. Evaluation of the in vitro cytotoxic activity of ursolic acid PLGA nanoparticles against pancreatic ductal adenocarcinoma cell lines. Materials (Basel). 2021;14(17):4917.","journal-title":"Materials (Basel)"},{"key":"3508_CR43","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.2147\/IJN.S139507","volume":"12","author":"X-J Liu","year":"2017","unstructured":"Liu X-J, Liang L, Xiu-Jun L, Yi L, Chun-Yan Z, Rui-Qi W, et al. Mithramycin-loaded mPEG-PLGA nanoparticles exert potent antitumor efficacy against pancreatic carcinoma. Int J Nanomed. 2017;12:5255\u201369.","journal-title":"Int J Nanomed"},{"issue":"2","key":"3508_CR44","doi-asserted-by":"publisher","first-page":"633","DOI":"10.3892\/ol.2021.12894","volume":"22","author":"S Matsumoto","year":"2021","unstructured":"Matsumoto S, Nakata K, Sagara A, Guan W, Ikenaga N, Ohuchida K, et al. Efficient pre-treatment for pancreatic cancer using chloroquine-loaded nanoparticles targeting pancreatic stellate cells. Oncol Lett. 2021;22(2):633.","journal-title":"Oncol Lett"},{"issue":"8","key":"3508_CR45","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.nano.2015.07.001","volume":"11","author":"RK Verma","year":"2015","unstructured":"Verma RK, Yu W, Singh SP, Shankar S, Srivastava RK. Anthothecol-encapsulated PLGA nanoparticles inhibit pancreatic cancer stem cell growth by modulating sonic hedgehog pathway. Nanomedicine (Lond). 2015;11(8):2061\u201370.","journal-title":"Nanomedicine (Lond)"},{"issue":"6","key":"3508_CR46","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1021\/acs.molpharmaceut.3c00983","volume":"21","author":"CP Dora","year":"2024","unstructured":"Dora CP, Kushwah V, Yadav V, Kuche K, Jain S. Gemcitabine-phospholipid complex loaded lipid nanoparticles for improving drug loading, stability, and efficacy against pancreatic cancer. Mol Pharm. 2024;21(6):2699\u2013712.","journal-title":"Mol Pharm"},{"key":"3508_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.biopha.2018.03.101","volume":"102","author":"G Arya","year":"2018","unstructured":"Arya G, Das M, Sahoo SK. Evaluation of curcumin loaded chitosan\/PEG blended PLGA nanoparticles for effective treatment of pancreatic cancer. Biomed Pharmacother. 2018;102:555\u201366.","journal-title":"Biomed Pharmacother"},{"issue":"9","key":"3508_CR48","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1080\/03639045.2018.1459674","volume":"44","author":"Z Daman","year":"2018","unstructured":"Daman Z, Faghihi H, Montazeri H. Salinomycin nanoparticles interfere with tumor cell growth and the tumor microenvironment in an orthotopic model of pancreatic cancer. Drug Dev Ind Pharm. 2018;44(9):1434\u201342.","journal-title":"Drug Dev Ind Pharm"},{"issue":"1","key":"3508_CR49","doi-asserted-by":"publisher","first-page":"32743","DOI":"10.1038\/srep32743","volume":"6","author":"RK Verma","year":"2016","unstructured":"Verma RK, Yu W, Shrivastava A, Shankar S, Srivastava RK. \u03b1-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (KrasG12D, and KrasG12D\/tp53R270H) mice. Sci Rep. 2016;6(1):32743.","journal-title":"Sci Rep"},{"issue":"4","key":"3508_CR50","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/03639045.2020.1747485","volume":"46","author":"MH Akhter","year":"2020","unstructured":"Akhter MH, Kumar S, Nomani S. Sonication tailored enhance cytotoxicity of naringenin nanoparticle in pancreatic cancer: Design, optimization, and in vitro studies. Drug Dev Ind Pharm. 2020;46(4):659\u201372.","journal-title":"Drug Dev Ind Pharm"},{"issue":"15","key":"3508_CR51","doi-asserted-by":"publisher","first-page":"8982","DOI":"10.1021\/acsomega.0c00793","volume":"5","author":"A Shetty","year":"2020","unstructured":"Shetty A, Nagesh PKB, Setua S, Hafeez BB, Jaggi M, Yallapu MM, et al. Novel Paclitaxel Nanoformulation Impairs De Novo Lipid Synthesis in Pancreatic Cancer Cells and Enhances Gemcitabine Efficacy. ACS Omega. 2020;5(15):8982\u201391.","journal-title":"ACS Omega"},{"key":"3508_CR52","doi-asserted-by":"publisher","first-page":"102027","DOI":"10.1016\/j.nano.2019.102027","volume":"20","author":"AE Massey","year":"2019","unstructured":"Massey AE, Sikander M, Chauhan N, Kumari S, Setua S, Shetty AB, et al. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomedicine (Lond). 2019;20:102027.","journal-title":"Nanomedicine (Lond)"},{"issue":"4","key":"3508_CR53","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1007\/s10853-019-04139-7","volume":"55","author":"Q Shao","year":"2020","unstructured":"Shao Q, Feng Y, Wang W, Wang M, Li B, El Tahchi M, et al. Drug carrier for sustained release of withaferin A for pancreatic cancer treatment. J Mater Sci. 2020;55(4):1702\u201314.","journal-title":"J Mater Sci"},{"issue":"113","key":"3508_CR54","doi-asserted-by":"publisher","first-page":"112393","DOI":"10.1039\/C6RA21997G","volume":"6","author":"W Deng","year":"2016","unstructured":"Deng W, Kautzka Z, Chen W, Goldys EM. PLGA nanocomposites loaded with verteporfin and gold nanoparticles for enhanced photodynamic therapy of cancer cells. RSC Adv. 2016;6(113):112393\u2013402.","journal-title":"RSC Adv"},{"key":"3508_CR55","doi-asserted-by":"crossref","unstructured":"Patra A, Satpathy S, Hussain MD. Nanodelivery and anticancer effect of a limonoid, nimbolide, in breast and pancreatic cancer cells. International journal of nanomedicine. 2019:8095\u2013104.","DOI":"10.2147\/IJN.S208540"},{"issue":"36","key":"3508_CR56","doi-asserted-by":"publisher","first-page":"E5328","DOI":"10.1073\/pnas.1611406113","volume":"113","author":"A Elgogary","year":"2016","unstructured":"Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, et al. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci. 2016;113(36):E5328\u201336.","journal-title":"Proc Natl Acad Sci"},{"issue":"10","key":"3508_CR57","doi-asserted-by":"publisher","first-page":"5536","DOI":"10.3390\/ijms23105536","volume":"23","author":"A Markowski","year":"2022","unstructured":"Markowski A, Jaromin A, Migda\u0142 P, Olczak E, Zygmunt A, Zaremba-Czogalla M, et al. Design and Development of a New Type of Hybrid PLGA\/Lipid Nanoparticle as an Ursolic Acid Delivery System against Pancreatic Ductal Adenocarcinoma Cells. Int J Mol Sci. 2022;23(10):5536.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3508_CR58","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.ijpharm.2016.07.048","volume":"511","author":"AK Rochani","year":"2016","unstructured":"Rochani AK, Balasubramanian S, RavindranGirija A, Raveendran S, Borah A, Nagaoka Y, et al. Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation. Int J Pharm. 2016;511(1):648\u201358.","journal-title":"Int J Pharm"},{"key":"3508_CR59","doi-asserted-by":"publisher","first-page":"116743","DOI":"10.1016\/j.biopha.2024.116743","volume":"175","author":"PM Giri","year":"2024","unstructured":"Giri PM, Kumar A, Salu P, Sathish V, Reindl K, Mallik S, et al. Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer. Biomed Pharmacother. 2024;175:116743.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"3508_CR60","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1002\/tox.23103","volume":"36","author":"MFS Jadid","year":"2021","unstructured":"Jadid MFS, Shademan B, Chavoshi R, Seyyedsani N, Aghaei E, Taheri E, et al. Enhanced anticancer potency of hydroxytyrosol and curcumin by PLGA\u2010PAA nano\u2010encapsulation on PANC\u20101 pancreatic cancer cell line. Environ Toxicol. 2021;36(6):1043\u201351.","journal-title":"Environ Toxicol"},{"key":"3508_CR61","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.msec.2014.11.027","volume":"47","author":"L Jaidev","year":"2015","unstructured":"Jaidev L, Krishnan UM, Sethuraman S. Gemcitabine loaded biodegradable PLGA nanospheres for in vitro pancreatic cancer therapy. Mater Sci Eng: C. 2015;47:40\u20137.","journal-title":"Mater Sci Eng: C"},{"key":"3508_CR62","doi-asserted-by":"crossref","unstructured":"Isazadeh A, Shadman B, Chavoshi R, Seyyedsani N, Aghaei E, Taheri E, et al. Enhanced Anticancer Potency of Hydroxytyrosol and Curcumin by PLGA-PAA Nano-Encapsulation on PANC-1 Pancreatic Cancer Cell Line. 2020.","DOI":"10.20944\/preprints202011.0215.v1"},{"issue":"8","key":"3508_CR63","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/pharmaceutics12080778","volume":"12","author":"TA Debele","year":"2020","unstructured":"Debele TA, Wu H-C, Wu S-R, Shan Y-S, Su W-P. Combination delivery of alpha-tocopheryl succinate and curcumin using a GSH-sensitive micelle (PAH-SS-PLGA) to treat pancreatic cancer. Pharmaceutics. 2020;12(8):778.","journal-title":"Pharmaceutics"},{"issue":"9","key":"3508_CR64","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/molecules22091553","volume":"22","author":"B Andrade-Carrera","year":"2017","unstructured":"Andrade-Carrera B, Clares B, No\u00e9 V, Mallandrich M, Calpena AC, Garc\u00eda ML, et al. Cytotoxic Evaluation of (2S)-5,7-Dihydroxy-6-prenylflavanone derivatives loaded PLGA nanoparticles against MiaPaCa-2 cells. Molecules. 2017;22(9):1553.","journal-title":"Molecules"},{"key":"3508_CR65","doi-asserted-by":"publisher","first-page":"120876","DOI":"10.1016\/j.ijpharm.2021.120876","volume":"606","author":"AI Mekkawy","year":"2021","unstructured":"Mekkawy AI, Naguib YW, Alhaj-Suliman SO, Wafa EI, Ebeid K, Acri T, et al. Paclitaxel anticancer activity is enhanced by the MEK 1\/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAFV600E melanoma-bearing mice. Int J Pharm. 2021;606:120876.","journal-title":"Int J Pharm"},{"issue":"9","key":"3508_CR66","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/nbt.3330","volume":"33","author":"E Blanco","year":"2015","unstructured":"Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941\u201351.","journal-title":"Nat Biotechnol"},{"key":"3508_CR67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.addr.2016.04.025","volume":"108","author":"JI Hare","year":"2017","unstructured":"Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST. Challenges and strategies in anti-cancer nanomedicine development: An industry perspective. Adv Drug Deliv Rev. 2017;108:25\u201338.","journal-title":"Adv Drug Deliv Rev"},{"issue":"23","key":"3508_CR68","doi-asserted-by":"publisher","first-page":"23223","DOI":"10.1021\/acsnano.3c06019","volume":"17","author":"D Wei","year":"2023","unstructured":"Wei D, Sun Y, Zhu H, Fu Q. Stimuli-responsive polymer-based nanosystems for cancer theranostics. ACS Nano. 2023;17(23):23223\u201361.","journal-title":"ACS Nano"},{"issue":"15","key":"3508_CR69","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.3390\/ijms26157055","volume":"26","author":"S Peshin","year":"2025","unstructured":"Peshin S, Takrori E, Kodali NA, Bashir F, Singal S. Advances in the management of pancreatic cancer: current strategies and emerging therapies. Int J Mol Sci. 2025;26(15):7055.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3508_CR70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","volume":"17","author":"L Buscail","year":"2020","unstructured":"Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153\u201368.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"3508_CR71","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrc.2016.108","volume":"17","author":"J Shi","year":"2017","unstructured":"Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20\u201337.","journal-title":"Nat Rev Cancer"},{"issue":"null","key":"3508_CR72","first-page":"2933","volume":"9","author":"S Arora","year":"2014","unstructured":"Arora S, Swaminathan SK, Kirtane A, Srivastava SK, Bhardwaj A, Singh S, et al. Synthesis, characterization, and evaluation of poly (D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150: potential implications for pancreatic cancer therapy. Int J Nanomedicine. 2014;9(null):2933\u201342.","journal-title":"Int J Nanomedicine"},{"issue":"7","key":"3508_CR73","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1080\/10837450.2020.1745232","volume":"25","author":"S Ceylan","year":"2020","unstructured":"Ceylan S, Bahadori F, Akbas F. Engineering of siRNA loaded PLGA nano-particles for highly efficient silencing of GPR87 gene as a target for pancreatic cancer treatment. Pharm Dev Technol. 2020;25(7):855\u201364.","journal-title":"Pharm Dev Technol"},{"issue":"10","key":"3508_CR74","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.3390\/cells10102734","volume":"10","author":"JY Jung","year":"2021","unstructured":"Jung JY, Ryu HJ, Lee S-H, Kim D-Y, Kim MJ, Lee EJ, et al. siRNA nanoparticle targeting PD-L1 activates tumor immunity and abrogates pancreatic cancer growth in humanized preclinical model. Cells. 2021;10(10):2734.","journal-title":"Cells"},{"key":"3508_CR75","doi-asserted-by":"publisher","unstructured":"Pan X, Zhu Q, Sun Y, Li L, Zhu Y, Zhao Z, et al. PLGA\/poloxamer nanoparticles loaded with EPAS1\u00a0siRNA for the treatment of pancreatic cancer in\u00a0vitro and\u00a0in\u00a0vivo Retraction in \/https:\/\/doi.org\/10.3892\/ijmm.2024.5459. Int J Mol Med. 2015;35(4):995\u20131002.","DOI":"10.3892\/ijmm.2024.5459"},{"issue":"4","key":"3508_CR76","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/jmcb\/mjy072","volume":"11","author":"X Zhou","year":"2019","unstructured":"Zhou X, Hao Q, Lu H. Mutant p53 in cancer therapy\u2014the barrier or the path. J Mol Cell Biol. 2019;11(4):293\u2013305.","journal-title":"J Mol Cell Biol"},{"issue":"4985","key":"3508_CR77","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1126\/science.1978757","volume":"250","author":"D Malkin","year":"1990","unstructured":"Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233\u20138.","journal-title":"Science"},{"issue":"6303","key":"3508_CR78","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/348747a0","volume":"348","author":"S Srivastava","year":"1990","unstructured":"Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348(6303):747\u20139.","journal-title":"Nature"},{"issue":"15","key":"3508_CR79","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.3390\/cancers13153920","volume":"13","author":"K-K Kuo","year":"2021","unstructured":"Kuo K-K, Hsiao P-J, Chang W-T, Chuang S-C, Yang Y-H, Wuputra K, et al. Therapeutic strategies targeting tumor suppressor genes in pancreatic cancer. Cancers. 2021;13(15):3920.","journal-title":"Cancers"},{"key":"3508_CR80","doi-asserted-by":"publisher","DOI":"10.1515\/biol-2022-0538","author":"F Wang","year":"2023","unstructured":"Wang F, Yan X, Hua Y, Song J, Liu D, Yang C, et al. PI3K\/AKT\/mTOR pathway and its related molecules participate in PROK1 silence-induced anti-tumor effects on pancreatic cancer. Open Life Sci. 2023. https:\/\/doi.org\/10.1515\/biol-2022-0538.","journal-title":"Open Life Sci"},{"issue":"17","key":"3508_CR81","doi-asserted-by":"publisher","first-page":"4393","DOI":"10.3390\/cancers13174393","volume":"13","author":"J Pahle","year":"2021","unstructured":"Pahle J, Kobelt D, Aumann J, Behrens D, Daberkow O, Mokritzkij M, et al. Effective oncoleaking treatment of pancreatic cancer by claudin-targeted suicide gene therapy with clostridium perfringens enterotoxin (CPE). Cancers. 2021;13(17):4393.","journal-title":"Cancers"},{"issue":"2","key":"3508_CR82","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.xphs.2015.11.015","volume":"105","author":"PL Turecek","year":"2016","unstructured":"Turecek PL, Bossard MJ, Schoetens F, Ivens IA. PEGylation of biopharmaceuticals: A review of chemistry and nonclinical safety information of approved drugs. J Pharm Sci. 2016;105(2):460\u201375.","journal-title":"J Pharm Sci"},{"key":"3508_CR83","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2147\/IJN.S121881","volume":"12","author":"P Rafiei","year":"2017","unstructured":"Rafiei P, Haddadi A. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile. Int J Nanomedicine. 2017;12:935\u201347.","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"3508_CR84","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1002\/jbm.a.35286","volume":"103","author":"MF Frasco","year":"2015","unstructured":"Frasco MF, Almeida GM, Santos\u2010Silva F, Pereira MdC, Coelho MA. Transferrin surface\u2010modified PLGA nanoparticles\u2010mediated delivery of a proteasome inhibitor to human pancreatic cancer cells. J Biomed Mater Res A. 2015;103(4):1476\u201384.","journal-title":"J Biomed Mater Res A"},{"issue":"1","key":"3508_CR85","first-page":"723158","volume":"2013","author":"H Song","year":"2013","unstructured":"Song H, Su C, Cui W, Zhu B, Liu L, Chen Z, et al. Folic Acid-Chitosan Conjugated Nanoparticles for Improving Tumor-Targeted Drug Delivery. Biomed Res Int. 2013;2013(1):723158.","journal-title":"Biomed Res Int"},{"issue":"6","key":"3508_CR86","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41571-020-0339-5","volume":"17","author":"M Scaranti","year":"2020","unstructured":"Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor \u03b1 in oncology. Nat Rev Clin Oncol. 2020;17(6):349\u201359.","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"3508_CR87","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1049\/nbt2.12139","volume":"17","author":"H Ghafaripour","year":"2023","unstructured":"Ghafaripour H, HomayouniTabrizi M, Karimi E, Barati NN. Lawsone encapsulated polylactic-co-glycolic acid nanoparticles modified with chitosan-folic acid successfully inhibited cell growth and triggered apoptosis in Panc-1 cancer cells. IET Nanobiotechnol. 2023;17(5):425\u201337.","journal-title":"IET Nanobiotechnol"},{"issue":"7","key":"3508_CR88","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.3390\/mi14071390","volume":"14","author":"J Ibarra","year":"2023","unstructured":"Ibarra J, Encinas-Basurto D, Almada M, Ju\u00e1rez J, Valdez MA, Barbosa S, et al. Gold half-shell-coated paclitaxel-loaded PLGA nanoparticles for the targeted chemo-photothermal treatment of cancer. Micromachines. 2023;14(7):1390.","journal-title":"Micromachines"},{"issue":"4","key":"3508_CR89","doi-asserted-by":"publisher","first-page":"4959","DOI":"10.1002\/jcp.27297","volume":"234","author":"C Serri","year":"2019","unstructured":"Serri C, Quagliariello V, Iaffaioli RV, Fusco S, Botti G, Mayol L, et al. Combination therapy for the treatment of pancreatic cancer through hyaluronic acid-decorated nanoparticles loaded with quercetin and gemcitabine: A preliminary in vitro study. J Cell Physiol. 2019;234(4):4959\u201369.","journal-title":"J Cell Physiol"},{"issue":"9","key":"3508_CR90","doi-asserted-by":"publisher","first-page":"777","DOI":"10.4161\/cbt.11.9.15050","volume":"11","author":"TM Brand","year":"2011","unstructured":"Brand TM, Iida M, Wheeler DL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011;11(9):777\u201392.","journal-title":"Cancer Biol Ther"},{"issue":"3","key":"3508_CR91","first-page":"1002","volume":"44","author":"H Masui","year":"1984","unstructured":"Masui H, Kawamoto T, Sato JD, Wolf B, Sato G, Mendelsohn J. Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies1. Can Res. 1984;44(3):1002\u20137.","journal-title":"Can Res"},{"issue":"4","key":"3508_CR92","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.ccr.2005.03.003","volume":"7","author":"S Li","year":"2005","unstructured":"Li S, Schmitz KR, Jeffrey PD, Wiltzius JJW, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301\u201311.","journal-title":"Cancer Cell"},{"issue":"42","key":"3508_CR93","doi-asserted-by":"publisher","first-page":"20261","DOI":"10.1039\/C9NR07257H","volume":"11","author":"WJ McDaid","year":"2019","unstructured":"McDaid WJ, Greene MK, Johnston MC, Pollheimer E, Smyth P, McLaughlin K, et al. Repurposing of Cetuximab in antibody-directed chemotherapy-loaded nanoparticles in EGFR therapy-resistant pancreatic tumours. Nanoscale. 2019;11(42):20261\u201373.","journal-title":"Nanoscale"},{"issue":"1","key":"3508_CR94","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1166\/jbn.2011.1238","volume":"7","author":"S Aggarwal","year":"2011","unstructured":"Aggarwal S, Yadav S, Gupta S. EGFR targeted PLGA nanoparticles using gemcitabine for treatment of pancreatic cancer. J Biomed Nanotechnol. 2011;7(1):137\u20138.","journal-title":"J Biomed Nanotechnol"},{"issue":"10","key":"3508_CR95","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.7150\/thno.15164","volume":"6","author":"L Xing","year":"2016","unstructured":"Xing L, Shi Q, Zheng K, Shen M, Ma J, Li F, et al. Ultrasound-Mediated Microbubble Destruction (UMMD) Facilitates the Delivery of CA19-9 Targeted and Paclitaxel Loaded mPEG-PLGA-PLL Nanoparticles in Pancreatic Cancer. Theranostics. 2016;6(10):1573\u201387.","journal-title":"Theranostics"},{"issue":"48","key":"3508_CR96","doi-asserted-by":"publisher","first-page":"80008","DOI":"10.18632\/oncotarget.13243","volume":"7","author":"J Ma","year":"2016","unstructured":"Ma J, Shen M, Xu CS, Sun Y, Duan YR, Du LF. Biodegradable double-targeted PTX-mPEG-PLGA nanoparticles for ultrasound contrast enhanced imaging and antitumor therapy in vitro. Oncotarget. 2016;7(48):80008\u201318.","journal-title":"Oncotarget"},{"issue":"6","key":"3508_CR97","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.ceb.2010.08.001","volume":"22","author":"A Yang","year":"2010","unstructured":"Yang A, Wilson NS, Ashkenazi A. Proapoptotic DR4 and DR5 signaling in cancer cells: toward clinical translation. Curr Opin Cell Biol. 2010;22(6):837\u201344.","journal-title":"Curr Opin Cell Biol"},{"key":"3508_CR98","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jconrel.2020.05.046","volume":"324","author":"MC Johnston","year":"2020","unstructured":"Johnston MC, Nicoll JA, Redmond KM, Smyth P, Greene MK, McDaid WJ, et al. DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models. J Control Release. 2020;324:610\u20139.","journal-title":"J Control Release"},{"issue":"12","key":"3508_CR99","doi-asserted-by":"publisher","first-page":"e951","DOI":"10.1038\/cddis.2013.481","volume":"4","author":"JS Riley","year":"2013","unstructured":"Riley JS, Hutchinson R, McArt DG, Crawford N, Holohan C, Paul I, et al. Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. Cell Death Dis. 2013;4(12):e951.","journal-title":"Cell Death Dis"},{"key":"3508_CR100","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","volume":"70","author":"CL Hattrup","year":"2008","unstructured":"Hattrup CL, Gendler SJ. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol. 2008;70:431\u201357.","journal-title":"Annu Rev Physiol"},{"issue":"39","key":"3508_CR101","doi-asserted-by":"publisher","first-page":"24198","DOI":"10.1074\/jbc.272.39.24198","volume":"272","author":"MD Burdick","year":"1997","unstructured":"Burdick MD, Harris A, Reid CJ, Iwamura T, Hollingsworth MA. Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J Biol Chem. 1997;272(39):24198\u2013202.","journal-title":"J Biol Chem"},{"issue":"3","key":"3508_CR102","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1166\/mex.2014.1160","volume":"4","author":"B Sivakumar","year":"2014","unstructured":"Sivakumar B, Aswathy RG, Nagaoka Y, Iwai S, Hasumura T, Venugopal K, et al. Augmented cellular uptake and antiproliferation against pancreatic cancer cells induced by targeted curcumin and SPION encapsulated PLGA nanoformulation. Mater Express. 2014;4(3):183\u201395.","journal-title":"Mater Express"},{"issue":"15","key":"3508_CR103","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.15252\/embj.201796632","volume":"36","author":"RJ Suckling","year":"2017","unstructured":"Suckling RJ, Korona B, Whiteman P, Chillakuri C, Holt L, Handford PA, et al. Structural and functional dissection of the interplay between lipid and Notch binding by human Notch ligands. EMBO J. 2017;36(15):2204\u201315.","journal-title":"EMBO J"},{"issue":"27","key":"3508_CR104","doi-asserted-by":"publisher","first-page":"14751","DOI":"10.1039\/D0NR02962A","volume":"12","author":"A Leach","year":"2020","unstructured":"Leach A, Smyth P, Ferguson L, Steven J, Greene MK, Branco CM, et al. Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature. Nanoscale. 2020;12(27):14751\u201363.","journal-title":"Nanoscale"},{"issue":"12","key":"3508_CR105","doi-asserted-by":"publisher","first-page":"6425","DOI":"10.3390\/ijms22126425","volume":"22","author":"S Clement","year":"2021","unstructured":"Clement S, Anwer AG, Pires L, Campbell J, Wilson BC, Goldys EM. Radiodynamic Therapy Using TAT Peptide-Targeted Verteporfin-Encapsulated PLGA Nanoparticles. Int J Mol Sci. 2021;22(12):6425.","journal-title":"Int J Mol Sci"},{"key":"3508_CR106","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","volume":"66","author":"N Bertrand","year":"2014","unstructured":"Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2\u201325.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"3508_CR107","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","volume":"1","author":"S Wilhelm","year":"2016","unstructured":"Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.","journal-title":"Nat Rev Mater"},{"key":"3508_CR108","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.biomaterials.2015.02.082","volume":"53","author":"S Khan","year":"2015","unstructured":"Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, et al. Nanoparticle formulation of ormeloxifene for pancreatic cancer. Biomaterials. 2015;53:731\u201343.","journal-title":"Biomaterials"},{"issue":"3","key":"3508_CR109","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.apsb.2018.12.009","volume":"9","author":"X Cao","year":"2019","unstructured":"Cao X, Hu Y, Luo S, Wang Y, Gong T, Sun X, et al. Neutrophil-mimicking therapeutic nanoparticles for targeted chemotherapy of pancreatic carcinoma. Acta Pharm Sin B. 2019;9(3):575\u201389.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"3508_CR110","doi-asserted-by":"publisher","first-page":"12613","DOI":"10.1038\/s41598-019-48959-8","volume":"9","author":"M Benguigui","year":"2019","unstructured":"Benguigui M, Weitz IS, Timaner M, Kan T, Shechter D, Perlman O, et al. Copper oxide nanoparticles inhibit pancreatic tumor growth primarily by targeting tumor initiating cells. Sci Rep. 2019;9(1):12613.","journal-title":"Sci Rep"},{"issue":"8","key":"3508_CR111","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1097\/MPA.0000000000000607","volume":"45","author":"JE Kobes","year":"2016","unstructured":"Kobes JE, Daryaei I, Howison CM, Bontrager JG, Sirianni RW, Meuillet EJ, et al. Improved Treatment of Pancreatic Cancer With Drug Delivery Nanoparticles Loaded With a Novel AKT\/PDK1 Inhibitor. Pancreas. 2016;45(8):1158\u201366.","journal-title":"Pancreas"},{"key":"3508_CR112","doi-asserted-by":"publisher","first-page":"101005","DOI":"10.1016\/j.drup.2023.101005","volume":"71","author":"W Zhang","year":"2023","unstructured":"Zhang W, Fan Y, Zhang J, Shi D, Yuan J, Ashrafizadeh M, et al. Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer. Drug Resist Updates. 2023;71:101005.","journal-title":"Drug Resist Updates"},{"issue":"2","key":"3508_CR113","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/pharmaceutics14020276","volume":"14","author":"MC Operti","year":"2022","unstructured":"Operti MC, Bernhardt A, Sincari V, Jager E, Grimm S, Engel A, et al. Industrial scale manufacturing and downstream processing of PLGA-based nanomedicines suitable for fully continuous operation. Pharmaceutics. 2022;14(2):276.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3508_CR114","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3390\/pharmaceutics14030614","volume":"14","author":"YW Lim","year":"2022","unstructured":"Lim YW, Tan WS, Ho KL, Mariatulqabtiah AR, Abu Kasim NH, Abd. Rahman N, et al. Challenges and complications of poly (lactic-co-glycolic acid)-based long-acting drug product development. Pharmaceutics. 2022;14(3):614.","journal-title":"Pharmaceutics"},{"key":"3508_CR115","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/978-3-319-16555-4_9","volume-title":"Nanotechnology-based precision tools for the detection and treatment of cancer","author":"L Miao","year":"2015","unstructured":"Miao L, Huang L. Exploring the tumor microenvironment with nanoparticles. In: Nanotechnology-based precision tools for the detection and treatment of cancer. 2015. p. 193\u2013226."},{"issue":"4","key":"3508_CR116","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/PPO.0000000000000140","volume":"21","author":"CJ Whatcott","year":"2015","unstructured":"Whatcott CJ, Han H, Von Hoff DD. Orchestrating the tumor microenvironment to improve survival for patients with pancreatic cancer: normalization, not destruction. The Cancer Journal. 2015;21(4):299\u2013306.","journal-title":"The Cancer Journal"},{"issue":"7","key":"3508_CR117","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1111\/cas.13630","volume":"109","author":"HY Tanaka","year":"2018","unstructured":"Tanaka HY, Kano MR. Stromal barriers to nanomedicine penetration in the pancreatic tumor microenvironment. Cancer Sci. 2018;109(7):2085\u201392.","journal-title":"Cancer Sci"},{"key":"3508_CR118","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3389\/fphar.2018.01260","volume":"9","author":"S Rezvantalab","year":"2018","unstructured":"Rezvantalab S, Drude NI, Moraveji MK, G\u00fcvener N, Koons EK, Shi Y, et al. PLGA-based nanoparticles in cancer treatment. Front Pharmacol. 2018;9:1260.","journal-title":"Front Pharmacol"},{"issue":"24","key":"3508_CR119","doi-asserted-by":"publisher","first-page":"6175","DOI":"10.3390\/cancers13246175","volume":"13","author":"MK Greene","year":"2021","unstructured":"Greene MK, Johnston MC, Scott CJ. Nanomedicine in pancreatic cancer: current status and future opportunities for overcoming therapy resistance. Cancers. 2021;13(24):6175.","journal-title":"Cancers"},{"key":"3508_CR120","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S560983","author":"J He","year":"2026","unstructured":"He J, Xue W, Li Y. Tumor microenvironment-responsive nanomedicine: monitoring and modulating the tumor microenvironment for precision cancer therapy. Int J Nanomedicine. 2026. https:\/\/doi.org\/10.2147\/IJN.S560983.","journal-title":"Int J Nanomedicine"},{"key":"3508_CR121","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/B978-0-323-91215-0.00004-2","volume-title":"Poly (lactic-co-glycolic acid)(PLGA) nanoparticles for drug delivery","author":"A Kumari","year":"2023","unstructured":"Kumari A, Mal A, Kaushik RY, Bandyopadhyaya R. PLGA-based nanoparticles for enhanced diagnosis and cancer therapy. In: Poly (lactic-co-glycolic acid)(PLGA) nanoparticles for drug delivery. Elsevier; 2023. p. 179\u2013210."},{"key":"3508_CR122","doi-asserted-by":"publisher","DOI":"10.1016\/j.cobme.2025.100625","author":"S Azimi","year":"2025","unstructured":"Azimi S. Intelligent nanoparticle design: unlocking the potential of AI for transformative drug delivery. Curr Opin Biomed Eng. 2025. https:\/\/doi.org\/10.1016\/j.cobme.2025.100625.","journal-title":"Curr Opin Biomed Eng"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03508-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03508-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03508-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:03:15Z","timestamp":1788890595000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03508-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":122,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3508"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03508-1","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"assertion":[{"value":"8 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"275"}}